Valuation: Nipro Corporation

Market Cap 262B 1.65B 1.42B 1.34B 1.22B 2.29B 158B 2.32B 15.67B 6.13B 78.9B 6.19B 6.05B P/E 2027 *
17.2x
P/E 2028 * 13.3x
Enterprise Value 771B 4.85B 4.19B 3.93B 3.58B 6.73B 464B 6.84B 46.1B 18.02B 232B 18.2B 17.8B EV / Sales 2027 *
1.1x
EV / Sales 2028 * 1.03x
Free-Float
84.43%
Yield 2027 *
2.27%
Yield 2028 * 2.85%
07-30 Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United States CI
07-29 Vat Holding AG agreed to acquire 100% stake in Atonarp Inc. from Nipro Corporation for CHF 110 million. CI
07-14 Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold MT
05-12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
05-12 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
05-01 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
03-11 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
02-09 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12-24 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
11-10 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/06/25 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/06/25 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/05/25 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
1 day+2.79%
Current month+21.02%
Current year+21.02%
3 years 8.23
Extreme 8.23
9.96
5 years 8.23
Extreme 8.23
9.96
10 years 8.23
Extreme 8.23
9.96
Manager TitleAgeSince
Director of Finance/CFO 57 01/06/2025
President 58 01/06/2025
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 81 26/06/2025
Director/Board Member 53 01/06/2009
Director/Board Member 58 01/06/2009
Change 5-day change 1-year change 3-year change Capi.($)
+2.79%-.--% - - 1.65B
-0.02%+3.19%-13.95%+4.85% 193B
+0.76%+4.72%-0.77%+9.75% 117B
+1.43%-2.07%+6.43%+67.25% 59.89B
+0.32%+3.92%+38.42%+65.14% 56.01B
+0.79%+3.70%-5.95%-35.11% 49.96B
-1.89%+5.90%+12.24%-22.47% 33.87B
+0.45%+1.45% - - 31.36B
+1.98%+12.62%-2.80%+25.91% 24.77B
+0.94%-1.31%+41.93%-12.62% 24.59B
Average +0.76%+3.69%+9.44%+12.84% 65.53B
Weighted average by Cap. +0.43%+3.41%+1.51%+13.55%

Financials

2027 *2028 *
Net sales 701B 4.4B 3.8B 3.57B 3.25B 6.11B 421B 6.21B 41.87B 16.37B 211B 16.53B 16.17B 729B 4.58B 3.96B 3.72B 3.38B 6.36B 438B 6.46B 43.56B 17.03B 219B 17.2B 16.82B
Net income 15.39B 96.74M 83.55M 78.51M 71.4M 134M 9.25B 136M 920M 360M 4.63B 363M 355M 19.95B 125M 108M 102M 92.55M 174M 11.99B 177M 1.19B 466M 6B 471M 461M
Net Debt 509B 3.2B 2.76B 2.6B 2.36B 4.44B 306B 4.51B 30.43B 11.9B 153B 12.01B 11.75B 489B 3.08B 2.66B 2.5B 2.27B 4.27B 294B 4.34B 29.24B 11.43B 147B 11.55B 11.3B
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,595.00JPY
Average target price
1,986.00JPY
Spread / Average Target
+24.51%

Quarterly revenue - Rate of surprise